May 25, 2023 4:05pm EDT Virios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement
May 15, 2023 7:05am EDT Virios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat Fibromyalgia
